Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
Ho CY, Ludovici DW, Maharoof US, Mei J, Sechler JL, Tuman RW, Strobel ED, Andraka L, Yen HK, Leo G, Li J, Almond H, Lu H, DeVine A, Tominovich RM, Baker J, Emanuel S, Gruninger RH, Middleton SA, Johnson DL, Galemmo RA Jr. Ho CY, et al. Among authors: ludovici dw. J Med Chem. 2005 Dec 29;48(26):8163-73. doi: 10.1021/jm050680m. J Med Chem. 2005. PMID: 16366598
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.
Lu T, Schubert C, Cummings MD, Bignan G, Connolly PJ, Smans K, Ludovici D, Parker MH, Meyer C, Rocaboy C, Alexander R, Grasberger B, De Breucker S, Esser N, Fraiponts E, Gilissen R, Janssens B, Peeters D, Van Nuffel L, Vermeulen P, Bischoff J, Meerpoel L. Lu T, et al. Among authors: ludovici d. Bioorg Med Chem Lett. 2018 Jul 1;28(12):2159-2164. doi: 10.1016/j.bmcl.2018.05.014. Epub 2018 May 8. Bioorg Med Chem Lett. 2018. PMID: 29779975
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP. Andries K, et al. Among authors: ludovici d. Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6. doi: 10.1128/AAC.48.12.4680-4686.2004. Antimicrob Agents Chemother. 2004. PMID: 15561844 Free PMC article.
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi PJ, Heeres J, Koymans LM, de Jonge MR, Van Aken KJ, Daeyaert FF, Das K, Arnold E, Janssen PA. Ludovici DW, et al. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2235-9. doi: 10.1016/s0960-894x(01)00412-7. Bioorg Med Chem Lett. 2001. PMID: 11527705
Arylglycine derivatives as potent transient receptor potential melastatin 8 (TRPM8) antagonists.
Zhu B, Xia M, Xu X, Ludovici DW, Tennakoon M, Youngman MA, Matthews JM, Dax SL, Colburn RW, Qin N, Hutchinson TL, Lubin ML, Brandt MR, Stone DJ, Flores CM, Macielag MJ. Zhu B, et al. Among authors: ludovici dw. Bioorg Med Chem Lett. 2013 Apr 1;23(7):2234-7. doi: 10.1016/j.bmcl.2013.01.062. Epub 2013 Feb 4. Bioorg Med Chem Lett. 2013. PMID: 23411075
Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues.
Ludovici DW, Kavash RW, Kukla MJ, Ho CY, Ye H, De Corte BL, Andries K, de Béthune MP, Azijn H, Pauwels R, Moereels HE, Heeres J, Koymans LM, de Jonge MR, Van Aken KJ, Daeyaert FF, Lewi PJ, Das K, Arnold E, Janssen PA. Ludovici DW, et al. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2229-34. doi: 10.1016/s0960-894x(01)00411-5. Bioorg Med Chem Lett. 2001. PMID: 11527704
15 results